Atea Pharmaceuticals, INC 10-Q quarterly reports

Atea Pharmaceuticals reported its Q2 2026 financial results, highlighting progress in its HCV and HEV programs, with topline results from the C-FORWARD Phase 3 trial anticipated in early Q1 2027.

Atea Pharmaceuticals, Inc. reported its first-quarter 2026 financial results, highlighting progress in its Hepatitis C (HCV) and Hepatitis E (HEV) development programs, with cash reserves expected to fund operations through 2027.

Atea Pharmaceuticals reports reduced net loss in Q3 2025, driven by a strategic pivot to its Hepatitis C virus (HCV) program and cost-cutting measures, while maintaining a strong cash position.

Atea Pharmaceuticals reports reduced Q2 2025 net loss and operating expenses, driven by a workforce reduction and discontinuation of its COVID-19 program, while advancing its lead HCV Phase 3 clinical trials.

Atea Pharmaceuticals announces Q1 2025 results, highlighting the start of patient enrollment for the Phase 3 HCV program and a strategic review to enhance stockholder value.

Atea Pharmaceuticals reports a net loss of $31.15 million for the third quarter of 2024, while advancing its hepatitis C virus (HCV) program.

Atea Pharmaceuticals has released its 10-Q filing for the second quarter of 2024, detailing financial results and providing updates on its clinical development programs, including bemnifosbuvir for COVID-19 and HCV.

Atea Pharmaceuticals reported its first quarter 2024 results, highlighting progress in its COVID-19 and Hepatitis C clinical programs.